Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of “Moderate Buy” by Analysts
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six ...
Investor's Business Daily on MSN10d
Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment
Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double ...
What is Leerink Partnrs’ Forecast for VIR Q2 Earnings?
Research analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for shares of Vir Biotechnology in a ...
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer
Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first ...
Vir Biotechnology Receives Buy Rating: Promising TCE Programs and Strategic Focus Boost Growth Outlook
Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) on January 13 and set a price target ...
Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong?
Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate ...
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why
Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and ...
Bank of America Securities Sticks to Their Hold Rating for Vir Biotechnology (VIR)
Bank of America Securities analyst Alec Stranahan maintained a Hold rating on Vir Biotechnology (VIR – Research Report) yesterday and set a ...
Vir Biotech upgraded at Morgan Stanley on cancer drug data
Vir Biotechnology (VIR) stock was upgraded by Morgan Stanley after the company posted trial data for two antitumor agents ...
Vir Biotechnology Reports Positive Phase 2 Results, Shares Surge by 58%
Following the publication of encouraging results from Phase 2 studies for two investigational cancer treatments, Vir ...
Business Wire10d
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
These initial results provide clinical support for Vir Biotechnology’s in-licensed PRO-XTEN™ masking technology, which is designed to enable the selective activation of TCEs in the tumor ...